Celecoxib Explained

Watchedfields:changed
Verifiedrevid:458612013
Width:220
Alt2:Space-filling model of the celecoxib molecule
Tradename:Celebrex, Onsenal, Elyxyb, others
Dailymedid:Celecoxib
Pregnancy Au:B3
Pregnancy Au Comment:[1]
Routes Of Administration:By mouth
Class:Cyclooxygenase-2 (COX-2) inhibitor
Atc Prefix:L01
Atc Suffix:XX33
Legal Au:S4
Legal Br:C1
Legal Br Comment:[2]
Legal Ca:Rx-only
Legal Nz:Prescription only
Legal Uk:POM
Legal Uk Comment:[3]
Legal Us:Rx-only
Legal Status:Rx-only
Bioavailability:Unknown[4]
Protein Bound:97% (mainly to serum albumin)
Metabolism:Liver (mainly CYP2C9)
Elimination Half-Life:7.8 hours; 11 hours (mild hepatic impairment); 13 hours (moderate-severe hepatic impairment)
Excretion:Faeces (57%), urine (27%)
Cas Number:169590-42-5
Pubchem:2662
Iuphar Ligand:2892
Drugbank:DB00482
Chemspiderid:2562
Unii:JCX84Q7J1L
Kegg:D00567
Chebi:41423
Chembl:118
Pdb Ligand:CEL
Iupac Name:4-[5-(4-Methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
C:17
H:14
F:3
N:3
O:2
S:1
Smiles:c1cc(C)ccc1c2cc(C(F)(F)F)nn2c3ccc(cc3)S(=O)(=O)N
Stdinchi:1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
Stdinchikey:RZEKVGVHFLEQIL-UHFFFAOYSA-N

Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID).[5] It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis.[5] It may also be used to decrease the risk of colorectal adenomas in people with familial adenomatous polyposis.[5] It is taken by mouth.[5] Benefits are typically seen within an hour.[5]

Common side effects include abdominal pain, nausea, and diarrhea.[5] Serious side effects may include heart attacks, strokes, gastrointestinal perforation, gastrointestinal bleeding, kidney failure, and anaphylaxis.[5] Use is not recommended in people at high risk for heart disease.[6] [7] The risks are similar to other NSAIDs, such as ibuprofen and naproxen.[8] Use in the later part of pregnancy or during breastfeeding is not recommended.[5]

Celecoxib was patented in 1993 and came into medical use in 1999.[9] It is available as a generic medication.[10] In 2021, it was the 98th most commonly prescribed medication in the United States, with more than 7million prescriptions.[11] [12]

Medical uses

Celecoxib is indicated for the treatment of osteoarthritis, rheumatoid arthritis, psoriatic arthritis, acute pain, musculoskeletal pain, painful menstruation, ankylosing spondylitis, juvenile rheumatoid arthritis, and to reduce the number of colon and rectal polyps in people with familial adenomatous polyposis.[5] It may be used in children with juvenile rheumatoid arthritis who are older than two years of age and weigh more than 10 kg (22 lb).[5]

For postoperative pain, it is more or less equal to ibuprofen.[13] For pain relief, it is similar to paracetamol (acetaminophen) at 3990 mg per day,[14] which is the first line treatment for osteoarthritis.[15] [16]

Evidence of effects is not clear as a number of studies done by the manufacturer have not been released for independent analysis.[17]

Familial adenomatous polyposis

It has been used to reduce colon and rectal polyps in people with familial adenomatous polyposis, but it is not known if it decreases rates of cancer,[5] so it is not a good choice for this reason.[5]

Adverse effects

People with prior history of ulcer disease or GI bleeding require special precaution. Moderate to severe liver impairment or GI toxicity can occur with or without warning symptoms in people treated with NSAIDs.

In October 2020, the U.S. Food and Drug Administration (FDA) required the drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid. They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.[20] [21]

Allergy

Celecoxib contains a sulfonamide moiety and may cause allergic reactions in those allergic to other sulfonamide-containing drugs. This is in addition to the contraindication in people with severe allergies to other NSAIDs. However, it has a low (reportedly 4%) chance of inducing cutaneous reactions among persons who have a history of such reactions to aspirin or nonselective NSAIDs. NSAIDs may cause serious skin adverse events, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis; events may occur without warning and in patients without prior known sulfa allergy. Use should be discontinued at first sign of rash (or any other hypersensitivity).

Heart attack and stroke

A 2013 meta-analysis of hundreds of clinical trials found that coxibs (the class of drugs that includes celecoxib) increase the risk of major cardiovascular problems by about 37% over placebo.[22] In 2016, a randomized trial provided strong evidence that treatment with celecoxib is not more likely to result in poor cardiovascular outcomes than treatment with naproxen or ibuprofen.[23] As a result, in 2018 an FDA advisory panel concluded that celecoxib poses no greater risk for causing heart attacks and strokes than the commonly-used NSAIDs ibuprofen or naproxen and recommended that the FDA consider changing its advice to physicians regarding celecoxib's safety.[8]

The COX-2 inhibitor rofecoxib (Vioxx) was removed from the market in 2004 due to its risk. Like all NSAIDs on the US market, celecoxib carries an FDA-mandated "black box warning" for cardiovascular and gastrointestinal risk. In February 2007, the American Heart Association warned that with respect to "patients with a prior history of or at high risk for cardiovascular disease... use of COX-2 inhibitors for pain relief should be limited to patients for whom there are no appropriate alternatives, and then, only in the lowest dose and for the shortest duration necessary."[6]

In 2005, a study published in the Annals of Internal Medicine found that cardiovascular effects of COX-2 inhibitors differ, depending on the drug.[24] Other COX-2-selective inhibitors, such as rofecoxib, have significantly higher myocardial infarction rates than celecoxib.[25] In April 2005, after an extensive review of data, the FDA concluded it was likely "that there is a 'class effect' for increased CV risk for all NSAIDs".[26] In a 2006 meta-analysis of randomized control studies, the cerebrovascular events associated with COX-2 inhibitors were examined, but no significant risks were found when compared to nonselective NSAIDs or placebos.[27]

Drug interactions

Celecoxib is predominantly metabolized by cytochrome P450 2C9. Caution must be exercised with concomitant use of 2C9 inhibitors, such as fluconazole, which can greatly elevate celecoxib serum levels.[19] If used concomitantly with lithium, celecoxib increases lithium plasma levels.[19] If used concomitantly with warfarin, celecoxib may result in increased risk of bleeding complications.[19] The risk of bleeding and gastric ulcers also increase further when selective serotonin reuptake inhibitors (SSRI) are used in combination with celecoxib.[28] The drug may increase the risk of kidney failure with angiotensin-converting enzyme-inhibitors, such as lisinopril, and diuretics, such as hydrochlorothiazide.[19]

Mechanism of action

Anti-inflammatory

A highly selective reversible inhibitor of the COX-2 isoform of cyclooxygenase, celecoxib inhibits the transformation of arachidonic acid to prostaglandin precursors. Therefore, it has analgesic and anti-inflammatory properties.[19] Nonselective NSAIDs (such as aspirin, naproxen, and ibuprofen) inhibit both COX-1 and COX-2. Inhibition of COX-1 (which celecoxib does not inhibit at therapeutic concentrations) inhibits the production of prostaglandins and the production of thromboxane A2, a platelet activator.[19] COX-1 is traditionally defined as a constitutively expressed "housekeeping" enzyme and plays a role in the protection of the gastrointestinal mucosa, kidney hemodynamics, and platelet thrombogenesis.[29] [30] COX-2, on the contrary, is extensively expressed in cells involved in inflammation and is upregulated by bacterial lipopolysaccharides, cytokines, growth factors, and tumor promoters.[29] [31] Celecoxib is approximately 10-20 times more selective for COX-2 inhibition over COX-1.[30] [32] It binds with its polar sulfonamide side chain to a hydrophilic side pocket region close to the active COX-2 binding site.[33] In theory, this selectivity allows celecoxib and other COX-2 inhibitors to reduce inflammation (and pain) while minimizing gastrointestinal adverse drug reactions (e.g. stomach ulcers) that are common with nonselective NSAIDs.[34]

Anti-cancer

For its use in reducing colon polyps, celecoxib affects genes and pathways involved in inflammation and malignant transformation in tumors, but not normal tissues.[35]

Celecoxib binds to Cadherin-11 (which may explain the reduction in cancer progression).

Structure-activity relationship

The Searle research group found the two appropriately substituted aromatic rings must reside on adjacent positions about the central ring for adequate COX-2 inhibition. Various modifications can be made to the 1,5-diarylpyrazole moiety to deduce the structure-activity relationship of celecoxib.[36] A para-sulfamoylphenyl at position 1 of the pyrazole was found to have a higher potency for COX-2 selective inhibition than a para-methoxyphenyl (see structures 1 and 2, below). In addition, a 4-(methylsulfonyl)phenyl or 4-sulfamoylphenyl is known to be necessary for COX-2 inhibition. For instance, replacing either of these entities with a –SO2NHCH3 substituent diminishes COX-2 inhibitory activity as noted with a very high inhibitory concentration-50 (see structures 3 – 5). At the 3-position of the pyrazole, a trifluoromethyl or difluoromethyl provides superior selectivity and potency compared to a fluoromethyl or methyl substitution (see structures 6 – 9).[36]

Celecoxib is compound 22; the 4-sulfamoylphenyl on the 1-pyrazol substituent is required for COX-2 inhibition and the 4-methyl on the 5-pyrazol system has low steric hindrance to maximize potency, while the 3-trifluoromethyl group provides superior selectivity and potency. To explain the selectivity of celecoxib, it is necessary to analyze the free energy of binding difference between the drug molecule and COX-1 compared to COX-2 enzymes. The structural modifications highlight the importance of binding to residue 523 in the side binding pocket of the cyclooxygenase enzyme, which is an isoleucine in COX-1 and a valine in COX-2.[37] This mutation appears to contribute to COX-2 selectivity by creating steric hindrance between the sulfonamide oxygen and the methyl group of Ile523 that effectively destabilizes the celecoxib-COX-1 complex.[37]

History

See also: Discovery and development of cyclooxygenase 2 inhibitors.

It was initially marketed by Pfizer for arthritis. Celecoxib and other COX-2 selective inhibitors, valdecoxib, parecoxib, and mavacoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.[38] [39]

Two lawsuits arose over discovery of celecoxib. Daniel L. Simmons of Brigham Young University (BYU) discovered the COX-2 enzyme in 1988,[40] and in 1991, BYU entered into a collaboration with Monsanto to develop drugs to inhibit it. Monsanto's pharmaceutical division was later purchased by Pfizer, and in 2006, BYU sued Pfizer for breach of contract, claiming Pfizer did not properly pay contractual royalties back to BYU.[41] A settlement was reached in April 2012, in which Pfizer agreed to pay $450 million.[42] [43] Other important discoveries in COX-2 were made at University of Rochester, which patented the discoveries. When the patent issued, the university sued Searle (later Pfizer) in a case called, University of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004). The court ruled in favor of Searle in 2004, holding in essence that the university had claimed a method requiring, yet provided no written description of, a compound that could inhibit COX-2 and therefore the patent was invalid.[44] [45]

According to the National Academy of Sciences, Philip Needleman, who was vice president of Monsanto in 1989 and president of Searle in 1993 oversaw research into COX-2 that led to the development of the anti-inflammatory drug celecoxib (Celebrex). He became senior executive vice president and chief scientist of Pharmacia from 2000 to 2003.[46] Celecoxib was discovered and developed by G. D. Searle & Company and was approved by the FDA on 31 December 1998.[47] It was co-promoted by Monsanto Company (parent company of Searle) and Pfizer under the brand name Celebrex. Monsanto merged with Pharmacia, from which the Medical Research Division was acquired by Pfizer, giving Pfizer ownership of Celebrex. The drug was at the core of a major patent dispute that was resolved in Searle's favor (later Pfizer) in 2004. In University of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004), the University of Rochester claimed that United States Pat. No. 6,048,850 (which claimed a method of inhibiting COX-2 in humans using a compound, without actually disclosing what that compound might be) covered drugs such as celecoxib. The court ruled in favor of Searle, holding in essence that the university had claimed a method requiring, yet provided no written description of, a compound that could inhibit COX-2 and therefore the patent was invalid.

After the withdrawal of rofecoxib from the market in September 2004, celecoxib enjoyed a robust increase in sales. However, the results of the APC trial in December of that year raised concerns that Celebrex might carry risks similar to those of rofecoxib, and Pfizer announced a moratorium on direct-to-consumer advertising of Celebrex soon afterwards. Sales reached $2 billion in 2006.[6] Prior to its availability in generic form, it was one of Pfizer's "best-selling drugs, amounting to more than $2.5 billion in sales [by 2012], and was prescribed to 2.4 million" people in 2011. By 2012, 33 million Americans had taken celecoxib.[48]

Pfizer resumed advertising Celebrex in magazines in 2006,[49] and resumed television advertising in April 2007 with an unorthodox, -minute advertisement which extensively discussed the adverse effects of Celebrex in comparison with other anti-inflammatory drugs. The ad drew criticism from the consumer advocacy group Public Citizen, which called the ad's comparisons misleading.[50] Pfizer responded to Public Citizen's concerns with assurances that they are truthfully advertising the risk and benefits of Celebrex as set forth by the FDA.[50]

Society and culture

Fabricated efficacy studies

Pfizer and its partner, Pharmacia presented findings from their study that Celebrex was "better in protecting the stomach from serious complications than other drugs." This became Celebrex's main selling point. However, following federal investigations it was revealed that Pfizer and Pharmacia "only presented the results from the first six months of a year long study rather than the whole thing." These partial results were then published in The Journal of the American Medical Association. In 2001, the US Food and Drug Administration (FDA) released the full results of the Pfizer and Pharmacia study which showed that they had withheld crucial data. By 2012, a federal judge unsealed "thousands of pages of internal documents and depositions" in a "long-running securities fraud case against Pfizer."

In March 2009, Scott S. Reuben, former chief of acute pain at Baystate Medical Center, Springfield, Massachusetts, revealed that the data for 21 studies he had authored for the efficacy of the drug (along with others such as Vioxx) had been fabricated. The analgesic effects of the drugs had been exaggerated. Reuben was also a former paid spokesperson for Pfizer. Although from 2002 to 2007 Pfizer underwrote much of Dr. Reuben's research and "many of his trials found that Celebrex and Lyrica, Pfizer drugs, were effective against postoperative pain," Pfizer was not aware of the fraudulent data.[51] None of the retracted studies were submitted to either the US Food and Drug Administration or the European Union's regulatory agencies prior to the drug's approval. Although Pfizer issued a public statement declaring, "It is very disappointing to learn about Dr. Scott Reuben's alleged actions. When we decided to support Dr. Reuben's research, he worked for a credible academic medical center and appeared to be a reputable investigator",[52] [53] the documents unsealed in 2012, revealed that by February 2000, Pharmacia employees had devised a strategy to present the findings.

Brand names

Pfizer markets celecoxib under the brand name Celebrex, and it is available as oral capsules containing 50, 100, 200 or 400 mg of celecoxib.

It is legally available in many jurisdictions as a generic under several brand names.[54] In the US, celecoxib was covered by three patents, two of which expired on 30 May 2014, and one of which (US RE44048[55]) was due to expire 2 December 2015. On 13 March 2014, that patent was found to be invalid for double patenting.[56] Upon the patent expiry on 30 May 2014, the FDA approved the first versions of generic celecoxib.[57]

In the US, Celebrex is marketed by Viatris after Upjohn was spun off from Pfizer.[58] [59] [60]

Research

Psychiatry

On the theory that inflammation plays a role in the pathogenesis of major mental disorders, celecoxib has been trialed for a number of psychiatric disorders, including major depression, bipolar disorder, and schizophrenia.[61] [62] [63] [64] [65]

Bipolar disorder

A meta-analysis considering trials of celecoxib as an adjunctive treatment in bipolar disorder was inconclusive citing low evidence quality.[61]

Familial adenomatous polyposis

It has been used to reduce colon and rectal polyps in people with familial adenomatous polyposis, but it is not known if it decreases rates of cancer,[5] so it is not a good choice for this reason.[5]

Cancer prevention

The use of celecoxib to reduce the risk of colorectal cancer has been investigated, but neither celecoxib nor any other drug is indicated for this use.[66] Small-scale clinical trials in very high-risk people (belonging to FAP families) showed celecoxib can prevent polyp growth. Hence, large-scale randomized clinical trials were undertaken.[67] Results show a 33 to 45% polyp recurrence reduction in people treated with celecoxib each day. However, serious cardiovascular events were significantly more frequent in the celecoxib-treated groups. Aspirin shows a similar (and possibly larger) protective effect,[68] [69] [70] has demonstrated cardioprotective effects and is significantly cheaper, but no head-to-head clinical trials have compared the two drugs.

Cancer treatment

Different from cancer prevention, cancer treatment is focused on the therapy of tumors that have already formed and have established themselves inside the patient. Many studies are going on to determine whether celecoxib might be useful for this latter condition.[71] However, during molecular studies in the laboratory, it became apparent that celecoxib could interact with other intracellular components besides its most famous target, COX-2. The discovery of these additional targets has generated much controversy, and the initial assumption that celecoxib reduces tumor growth primarily by the inhibition of COX-2 became contentious.[72]

Certainly, the inhibition of COX-2 is paramount for the anti-inflammatory and analgesic function of celecoxib. However, whether inhibition of COX-2 also plays a dominant role in this drug's anticancer effects is unclear. For example, a recent study with malignant tumor cells showed celecoxib could inhibit the growth of these cells in vitro, but COX-2 played no role in this outcome; even more strikingly, the anticancer effects of celecoxib were also obtained with the use of cancer cell types that do not even contain COX-2.[73] Karen Seibert and colleagues have published research showing antiangiogenic and antitumor activity of celecoxib in animal models.[74]

Additional support for the idea that other targets besides COX-2 are important for celecoxib's anticancer effects has come from studies with chemically modified versions of celecoxib. Several dozen analogs of celecoxib were generated with small alterations in their chemical structures.[75] Some of these analogs retained COX-2 inhibitory activity, whereas many others did not. However, when the ability of all these compounds to kill tumor cells in cell culture was investigated, the antitumor potency did not at all depend on whether or not the respective compound could inhibit COX-2, showing the inhibition of COX-2 was not required for the anticancer effects.[75] [76] One of these compounds, 2,5-dimethyl-celecoxib, which entirely lacks the ability to inhibit COX-2, actually displayed stronger anticancer activity than celecoxib.[77]

Further reading

External links

Notes and References

  1. Web site: Celecoxib (Celebrex) Use During Pregnancy . Drugs.com . 4 May 2020 . 5 May 2020 . 25 January 2021 . https://web.archive.org/web/20210125072333/https://www.drugs.com/pregnancy/celecoxib.html . live .
  2. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  3. Web site: Celebrex 100mg capsule - Summary of Product Characteristics (SmPC) . (emc) . 13 January 2020 . 5 May 2020 . 6 August 2020 . https://web.archive.org/web/20200806222736/https://www.medicines.org.uk/emc/product/5533/smpc . live .
  4. McCormack PL . Celecoxib: a review of its use for symptomatic relief in the treatment of Osteoarthritis, Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis . Drugs . 71 . 18 . 2457–89 . December 2011 . 22141388 . 10.2165/11208240-000000000-00000 . 71357689 .
  5. Web site: Celecoxib Monograph for Professionals . Drugs.com . American Society of Health-System Pharmacists . 11 November 2019 . 5 May 2020 . 20 May 2019 . https://web.archive.org/web/20190520124313/https://www.drugs.com/monograph/celecoxib.html . live .
  6. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA . Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association . Circulation . 115 . 12 . 1634–42 . March 2007 . 17325246 . 10.1161/circulationaha.106.181424 . free .
  7. Web site: Should you still take Celebrex? . . August 2009 . 27 December 2015 . 18 December 2015 . https://web.archive.org/web/20151218111927/http://www.consumerreports.org/cro/2012/05/should-you-still-take-celebrex/index.htm . live .
  8. News: Stein R . FDA Panel Affirms Safety Of Painkiller Celebrex. 19 May 2018. NPR. 25 April 2018. 20 May 2018. https://web.archive.org/web/20180520123906/https://www.npr.org/sections/health-shots/2018/04/25/605226604/fda-panel-affirms-safety-of-painkiller-celebrex. live.
  9. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery . 2006 . John Wiley & Sons . 9783527607495 . 522 . 13 October 2020 . 27 April 2021 . https://web.archive.org/web/20210427093939/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA522 . live .
  10. Book: British national formulary : BNF 76. 2018. Pharmaceutical Press. 9780857113382. 1097–1098. 76.
  11. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  12. Web site: Celecoxib - Drug Usage Statistics . ClinCalc . 14 January 2024.
  13. Derry S, Moore RA . Single dose oral celecoxib for acute postoperative pain in adults . The Cochrane Database of Systematic Reviews . 10 . 10 . CD004233 . October 2013 . 24150982 . 10.1002/14651858.CD004233.pub4 . 4161494 .
  14. Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM . Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials . Rheumatology . 46 . 1 . 135–40 . January 2007 . 16777855 . 10.1093/rheumatology/kel195 . free . 10072/15035 . free .
  15. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P . OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence . Osteoarthritis and Cartilage . 15 . 9 . 981–1000 . September 2007 . 17719803 . 10.1016/j.joca.2007.06.014 . free .
  16. Flood J . The role of acetaminophen in the treatment of osteoarthritis . The American Journal of Managed Care . 16 . Suppl . S48–54 . March 2010 . 20297877 .
  17. Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P . Celecoxib for osteoarthritis . The Cochrane Database of Systematic Reviews . 5 . CD009865 . May 2017 . 7 . 28530031 . 6481745 . 10.1002/14651858.CD009865.pub2 .
  18. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M . Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention . The New England Journal of Medicine . 352 . 11 . 1071–80 . March 2005 . 15713944 . 10.1056/NEJMoa050405 . free .
  19. Web site: Celebrex- celecoxib capsule . DailyMed . 31 May 2019 . 5 May 2020 . 24 February 2021 . https://web.archive.org/web/20210224181140/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226 . live .
  20. FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications . U.S. Food and Drug Administration (FDA) . 15 October 2020 . 15 October 2020 . 16 October 2020 . https://web.archive.org/web/20201016180003/https://www.fda.gov/news-events/press-announcements/fda-warns-using-type-pain-and-fever-medication-second-half-pregnancy-could-lead-complications . live .
  21. Web site: NSAIDs may cause rare kidney problems in unborn babies . U.S. Food and Drug Administration . 21 July 2017 . 15 October 2020 . 17 October 2020 . https://web.archive.org/web/20201017014419/https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic . live .
  22. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C . Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials . Lancet . 382 . 9894 . 769–79 . August 2013 . 23726390 . 3778977 . 10.1016/S0140-6736(13)60900-9 .
  23. Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM . Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis . The New England Journal of Medicine . 375 . 26 . 2519–29 . December 2016 . 27959716 . 10.1056/NEJMoa1611593 . free .
  24. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL . Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction . Annals of Internal Medicine . 142 . 3 . 157–64 . February 2005 . 15684203 . 10.7326/0003-4819-142-3-200502010-00005 . free .
  25. Mukherjee D, Nissen SE, Topol EJ . Risk of cardiovascular events associated with selective COX-2 inhibitors . JAMA . 286 . 8 . 954–9 . 2001 . 11509060 . 10.1001/jama.286.8.954 .
  26. Web site: Jenkins JK, Seligman PJ . Analysis and recommendations for Agency action regarding nonsteroidal anti-inflammatory drugs and cardiovascular risk [decision memorandum] ]. https://web.archive.org/web/20050909082236/https://www.fda.gov/cder/drug/infopage/cox2/NSAIDdecisionMemo.pdf . dead . 9 September 2005 . 6 April 2005 . U.S. Food and Drug Administration (FDA) .
  27. Chen LC, Ashcroft DM . Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials . Journal of Clinical Pharmacy and Therapeutics . 31 . 6 . 565–76 . December 2006 . 17176361 . 10.1111/j.1365-2710.2006.00774.x . 40738580 . free .
  28. Turner MS, May DB, Arthur RR, Xiong GL . Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks . Journal of Internal Medicine . 261 . 3 . 205–213 . March 2007 . 17305643 . 10.1111/j.1365-2796.2006.01720.x . 41772614 . free .
  29. Mathew ST, Devi SG, Prasanth VV, Vinod B . Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review . ISRN Pharmacology . 2011 . 480291 . 2011 . 22084715 . 3197256 . 10.5402/2011/480291 . free .
  30. Book: Katzung BG . Basic & clinical pharmacology . 2007 . McGraw-Hill Medical . New York . 9780071451536 . 579 . 10th .
  31. Shi S, Klotz U . Clinical use and pharmacological properties of selective COX-2 inhibitors . European Journal of Clinical Pharmacology . 64 . 3 . 233–52 . March 2008 . 17999057 . 10.1007/s00228-007-0400-7 . 24063728 .
  32. Conaghan PG . A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity . Rheumatology International . 32 . 6 . 1491–502 . June 2012 . 22193214 . 3364420 . 10.1007/s00296-011-2263-6 .
  33. Book: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM . Pharmacotherapy A Pathophysiologic Approach . 2008 . McGraw-Hill Medical . New York . 978-0-07-147899-1 . 7th.
  34. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ . ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents . Journal of the American College of Cardiology . 52 . 18 . 1502–17 . October 2008 . 19017521 . 10.1016/j.jacc.2008.08.002 . free .
  35. Half E, Arber N . Colon cancer: preventive agents and the present status of chemoprevention . Expert Opinion on Pharmacotherapy . 10 . 2 . 211–9 . February 2009 . 19236194 . 10.1517/14656560802560153 . 72411967 .
  36. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC . Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib) . Journal of Medicinal Chemistry . 40 . 9 . 1347–65 . April 1997 . 9135032 . 10.1021/jm960803q .
  37. Price ML, Jorgensen WL . Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations . Bioorganic & Medicinal Chemistry Letters . 11 . 12 . 1541–4 . June 2001 . 11412976 . 10.1016/s0960-894x(00)00522-9 .
  38. News: Langreth R . The Chemical Cobbler. Forbes. 23 June 2003. 15 April 2018. 16 April 2018. https://web.archive.org/web/20180416013759/https://www.forbes.com/global/2003/0623/050.html. live.
  39. Dr. John Talley: 2001 St. Louis Awardee. Chemical Bond. May 2001. 52. 5. 2. https://web.archive.org/web/20180415180802/http://www.stlacs.org/Bonds/2001May.pdf. 15 April 2018.
  40. Web site: University sues Pfizer over COX-2 research . Yajnik J . 27 October 2006 . . 11 November 2010 . 3 February 2009 . https://web.archive.org/web/20090203140727/http://www.the-scientist.com/news/display/25408/ . dead .
  41. Web site: Deseret News . 28 October 2009 . Judge orders Pfizer to pay BYU $852K for suit delays . Linda Thomson . 23 November 2009 . 31 October 2009 . https://web.archive.org/web/20091031124503/http://www.deseretnews.com/article/705340277/Judge-orders-Pfizer-to-pay-BYU-852K-for-suit-delays.html . live .
  42. News: Harvey T . Pfizer, BYU settle Celebrex lawsuit for $450M . . 1 May 2012 . 22 July 2012 . 3 March 2016 . https://web.archive.org/web/20160303220047/http://www.sltrib.com/sltrib/entertainment/54024947-79/byu-pfizer-settlement-simmons.html.csp . live .
  43. News: Pfizer Settles B.Y.U. Lawsuit Over Development of Celebrex . . 1 May 2012 . . 5 May 2020 . 27 December 2017 . https://web.archive.org/web/20171227132546/http://www.nytimes.com/2012/05/02/health/pfizer-settles-byu-lawsuit-over-development-of-celebrex.html . live .
  44. Web site: Reach-Through Claims Declared Invalid . 31 December 2012 . 22 February 2014 . https://web.archive.org/web/20140222060537/http://www.hodgsonruss.com/Home/Practice_Areas/Alphabetical_Listing/Intellectual_Property_Technology/Articles/20012004Articles/Reach-ThroughClaimsDeclaredInvalid . live .
  45. Ranjana Kadle (2004) CAFC Court Decision Reach-Through Claims Declared Invalid
  46. Web site: Philip Needleman . National Academy of Sciences . 15 June 2015 . 28 December 2015 . 7 January 2016 . https://web.archive.org/web/20160107133428/http://www.nasonline.org/news-and-multimedia/podcasts/interviews/philip-needleman.html?referrer=https%3A%2F%2Fwww.google.ca%2F . live .
  47. Web site: Drug Approval Package: Celebrex (Celecoxib) NDA# 20-998 . U.S. Food and Drug Administration (FDA) . 24 December 1999 . 5 May 2020 . 27 March 2019 . https://web.archive.org/web/20190327103438/https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20998.cfm . live .
  48. News: In Documents on Pain Drug, Signs of Doubt and Deception . . 24 June 2012 . 27 December 2015 . Thomas K . 3 January 2016 . https://web.archive.org/web/20160103151323/http://www.nytimes.com/2012/06/25/health/in-documents-on-pain-drug-celebrex-signs-of-doubt-and-deception.html . live .
  49. News: Berenson A . Celebrex Ads Are Back, Dire Warnings and All . The New York Times . 29 April 2006 . 21 February 2017 . 7 January 2016 . https://web.archive.org/web/20160107133428/http://www.nytimes.com/2006/04/29/business/media/29celebrex.html . live .
  50. News: Saul S . Celebrex Commercial, Long and Unconventional, Draws Criticism . The New York Times . 10 April 2007 . 21 February 2017 . 17 January 2018 . https://web.archive.org/web/20180117060825/http://www.nytimes.com/2007/04/10/business/media/10celebrex.html . live .
  51. News: Doctor Admits Pain Studies Were Frauds, Hospital Says . . 11 March 2009 . 27 December 2015 . Harris G . 17 May 2017 . https://web.archive.org/web/20170517184147/http://www.nytimes.com/2009/03/11/health/research/11pain.html . live .
  52. News: Top Pain Scientist Fabricated Data in Studies, Hospital Says . . Winstein KJ . 11 March 2009 . subscription . 3 August 2017 . 30 August 2017 . https://web.archive.org/web/20170830223401/https://www.wsj.com/articles/SB123672510903888207 . live .
  53. Web site: Associated Press, Mar 11, 2009, Mass. doctor accused of faking pain pill data . dead . https://web.archive.org/web/20090316103119/https://www.google.com/hostednews/ap/article/ALeqM5jjpBsTFN9SEtQu-xyDltivC2GJ8AD96S2KVO0 . 16 March 2009 .
  54. Web site: Celecoxib . Drugs.com . 4 May 2020 . 5 May 2020 . 10 March 2016 . https://web.archive.org/web/20160310184046/http://www.drugs.com/international/celecoxib.html . live .
  55. Web site: US Re-issued Patent RE44048 . 10 November 2016 . 9 January 2017 . https://web.archive.org/web/20170109190350/https://www.google.com/patents/USRE44048 . live .
  56. Web site: Parloff R . Judge cuts 18 months off patent life of Pfizer's Celebrex . . 13 March 2014 . 5 May 2020 . 25 July 2017 . https://web.archive.org/web/20170725162355/http://fortune.com/2014/03/13/judge-cuts-18-months-off-patent-life-of-pfizers-celebrex/ . live .
  57. FDA approves first generic versions of celecoxib . U.S. Food and Drug Administration (FDA) . 31 May 2014 . https://web.archive.org/web/20140531020104/https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm399428.htm . 31 May 2014 . dead . 5 May 2020.
  58. Web site: Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan . Pfizer . Business Wire . 16 November 2020 . 17 June 2024.
  59. Web site: Celebrex . Pfizer . 17 June 2024.
  60. Web site: Brands . Viatris . 16 November 2020 . 17 June 2024.
  61. Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, Carrà G . Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials . Journal of Psychiatric Research . September 2021 . 143 . 230–238 . 10.1016/j.jpsychires.2021.09.018. 34509090 . 237485915 .
  62. Müller N, Myint AM, Krause D, Weidinger E, Schwarz MJ . Anti-inflammatory treatment in schizophrenia . Progress in Neuro-Psychopharmacology & Biological Psychiatry . 42 . 146–53 . April 2013 . 23178230 . 10.1016/j.pnpbp.2012.11.008 . 22078590 .
  63. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY . Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis . Progress in Neuro-Psychopharmacology & Biological Psychiatry . 48 . 79–85 . January 2014 . 24056287 . 10.1016/j.pnpbp.2013.09.006 . 35885429 .
  64. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS . Inflamed moods: a review of the interactions between inflammation and mood disorders . Progress in Neuro-Psychopharmacology & Biological Psychiatry . 53 . 23–34 . August 2014 . 24468642 . 10.1016/j.pnpbp.2014.01.013 . 32289214 .
  65. Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A, Oliveira J, Le Guen E, Marlinge E, Tamouza R, Leboyer M . Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review . Acta Psychiatrica Scandinavica . 129 . 3 . 163–79 . March 2014 . 24215721 . 10.1111/acps.12211 . 23482349 .
  66. Rial NS, Zell JA, Cohen AM, Gerner EW . Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer . . 6 . 4 . 507–17 . August 2012 . 22928902 . 3587976 . 10.1586/egh.12.23 .
  67. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET . Celecoxib for the prevention of sporadic colorectal adenomas . The New England Journal of Medicine . 355 . 9 . 873–84 . August 2006 . 16943400 . 10.1056/NEJMoa061355 . free .
  68. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU . A randomized trial of aspirin to prevent colorectal adenomas . The New England Journal of Medicine . 348 . 10 . 891–9 . March 2003 . 12621133 . 10.1056/NEJMoa021735 . free .
  69. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R . A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer . The New England Journal of Medicine . 348 . 10 . 883–90 . March 2003 . 12621132 . 10.1056/NEJMoa021633 . free .
  70. Bosetti C, Talamini R, Franceschi S, Negri E, Garavello W, La Vecchia C . Aspirin use and cancers of the upper aerodigestive tract . British Journal of Cancer . 88 . 5 . 672–4 . March 2003 . 12618872 . 2376339 . 10.1038/sj.bjc.6600820 .
  71. Dannenberg AJ, Subbaramaiah K . Targeting cyclooxygenase-2 in human neoplasia: rationale and promise . Cancer Cell . 4 . 6 . 431–6 . December 2003 . 14706335 . 10.1016/S1535-6108(03)00310-6 . free .
  72. Schönthal AH . Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy . British Journal of Cancer . 97 . 11 . 1465–8 . December 2007 . 17955049 . 2360267 . 10.1038/sj.bjc.6604049 .
  73. Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schönthal AH . COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro . Molecular Cancer . 7 . 1 . 38 . May 2008 . 18485224 . 2396175 . 10.1186/1476-4598-7-38 . free .
  74. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K . Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors . Cancer Research . 60 . 5 . 1306–1311 . March 2000 . 10728691 .
  75. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS . Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents . Journal of the National Cancer Institute . 94 . 23 . 1745–57 . December 2002 . 12464646 . 10.1093/jnci/94.23.1745 . free .
  76. Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA . Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs . Expert Opinion on Investigational Drugs . 17 . 2 . 197–208 . February 2008 . 18230053 . 10.1517/13543784.17.2.197 . 21093404 .
  77. Schönthal AH . Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy . Neurosurgical Focus . 20 . 4 . E21 . April 2006 . 16709027 . 10.3171/foc.2006.20.4.14 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Celecoxib".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.